BioSpace News Archive

Biofrontera AG, an international biopharmaceutical company, decided its American Depositary Shares should be delisted from the Nasdaq Capital Market and its reporting obligations with the Securities and Exchange Commission should be deregistered and terminated.

Amring Pharmaceuticals Inc. announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal ® ), and has begun commercialization activities.

In 2021, BioGenerator, the startup arm of BioSTL, invested more than $3.3 million into 18 St. Louis startup companies. Eight of those companies earned first-time investments.

Patient group RETpositive and LUNGevity Foundation today announced the 2022 recipients of the first RETpositive/LUNGevity Translational Research Award for RET-Positive Lung Cancer.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022.

Vera Therapeutics, Inc. (“Vera”), today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters’ option to purchase up to 748,959 additional shares.

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced results for its fourth quarter and fiscal year ended December 31, 2021.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the fiscal year ended December 31, 2021.

Travere Therapeutics, Inc. announced that on February 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 70,600 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 45,600 shares of its common stock.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year ended December 31, 2021.